Copper radiopharmaceuticals for theranostic applications.

Eur J Med Chem

Institut de Chimie Moléculaire de l'Université de Bourgogne (ICMUB), UMR CNRS 6302, P2DA Team, Université de Bourgogne, 21000, Dijon, France. Electronic address:

Published: September 2018

The growing advancement in nuclear medicine challenges researchers from several different fields to integrate imaging and therapeutic modalities in a theranostic radiopharmaceutical, which can be defined as a molecular entity with readily replaceable radioisotope to provide easy switch between diagnostic and therapeutic applications for efficient and patient-friendly treatment of diseases. For such a reason, the diagnostic and therapeutic potential of all five medical radionuclides of copper have thoroughly been investigated as they boost the hope for development of successful radiotheranostics. To facilitate the mutual understanding between all different specialists working on this multidisciplinary field, we summarized the recent updates in copper-based nuclear medicine, with specific attention to the potential theranostic applications. Thereby, this review paper is focused on the current achievements in the copper-related complementary fields, such as synthetic and nuclear chemistry, biological assessment of radiopharmaceuticals, design and development of nanomaterials for multimodal theranostic implications. This work includes: i) description of available copper radionuclide production methods; ii) analyses of the synthetic strategies for development of improved copper radiopharmaceuticals; iii) summary of reported clinical data and recent preclinical studies from the last five years on biological applicability of copper radiopharmaceuticals; and iv) illustration of some sophisticated multimodal nanotheranostic agents that comprise several imaging and therapeutic modalities. Significant advancement can be seen in the synthetic procedures, which enables the broader implication of pretargeting approaches via bioorthogonal click reactions, as well as in the nanotechnology methods for biomimetic construction of biocompatible multimodal copper theranostics. All this gives the hope that personalized treatment of various diseases can be achieved by copper theranostics in the near future.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2018.08.051DOI Listing

Publication Analysis

Top Keywords

copper radiopharmaceuticals
12
theranostic applications
8
nuclear medicine
8
imaging therapeutic
8
therapeutic modalities
8
diagnostic therapeutic
8
treatment diseases
8
copper theranostics
8
copper
7
theranostic
4

Similar Publications

State of the art and future perspectives of new radionuclides in Nuclear Medicine.

Rev Esp Med Nucl Imagen Mol (Engl Ed)

January 2025

Unidad de Radiofarmacia, Servicio de Medicina Nuclear Clínica Universidad de Navarra, Madrid, Spain.

This continuing education analyzes recent advances in Nuclear Medicine focused on the development of new radiopharmaceuticals that improve both the diagnosis and treatment of complex diseases. The focus is on teragnosis, which combines diagnosis and treatment by means of pairs of radiopharmaceuticals directed to the same molecular target, which allows the personalization of treatments. This first part specifically reviews the teragnostic pairs copper-64/copper-67, lead-212/lead-203 and scandium-44/scandium-47, highlighting their physical characteristics, methods of production and potential clinical applications.

View Article and Find Full Text PDF

: Fibroblast activation protein (FAP)-targeted theranostic radiopharmaceuticals have shown desired tumor-to-background organ selectivity due to the ubiquitous presence of FAP within the tumor microenvironment. However, suboptimal tumor retention and fast clearance have hindered their use to deliver effective cancer therapies. With well-documented FAP-targeting moieties and linkers appending them to optimal chelators, the development of copper radiopharmaceuticals has attracted considerable interest, given the fact that an ideal theranostic pair of copper radionuclides (Cu: t = 12.

View Article and Find Full Text PDF

Evaluation of Dynamic Light Scattering as an Effective Quality Control Method for Aggregates in Radiolabeled Antibodies.

J Med Chem

January 2025

Department of Molecular Medicine, Brain Korea 21 Four KNU Convergence Educational, Program of Biomedical Sciences for Creative Future Talents, School of Medicine, Kyungpook National University, Daegu 41944, Korea.

Radiolabeled antibodies are promising for targeted cancer imaging, but their structural integrity may suffer during bioconjugation and radiolabeling, leading to undetected aggregation. This study evaluates dynamic light scattering (DLS) as a complementary method to size-exclusion high-performance liquid chromatography (SEC-HPLC) for detecting aggregation in radiolabeled antibodies. Trastuzumab was conjugated with a NOTA bifunctional chelator at various ratios, radiolabeled with [Cu]CuCl, and analyzed by using DLS and SEC-HPLC before and after purification.

View Article and Find Full Text PDF

Development of a fibrin-targeted theranostic for gastric cancer.

Sci Transl Med

December 2024

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.

Patients with advanced gastric cancer (GCa) have limited treatment options, and alternative treatment approaches are necessary to improve their clinical outcomes. Because fibrin is abundant in gastric tumors but not in healthy tissues, we hypothesized that fibrin could be used as a high-concentration depot for a high-energy beta-emitting cytotoxic radiopharmaceutical delivered to tumor cells. We showed that fibrin is present in 64 to 75% of primary gastric tumors and 50 to 100% of metastatic gastric adenocarcinoma cores.

View Article and Find Full Text PDF

Copper radioisotopes can be used for imaging as well as for therapy and, thus, can form ideal theranostic pairs. The Cu(II) complexes of cross-bridged cyclam (cb-cyclam) derivatives are considered to be highly stable . However, the complexes are mostly formed under harsh conditions not compatible with sensitive biomolecules.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!